Inhoudsopgave:
|
\u003ci\u003eNanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-morbidity Factors Part B, Volume 172\u003c/i\u003e in the \u003ci\u003eInternational Review of Neurobiology\u003c/i\u003e series, highlights new advances in the field with this new volume presenting interesting chapters on Spinal cord injury induced exacerbation of Alzheimer's disease pathophysiology in the cord is reduced by topical application of nanowired cerebrolysin and antibodies to tumor necrosis factor alpha, Nanodelivery of histamine H3 receptor inverse agonist BF-2549 with clobenpropit a H3 receptor antagonist and H4 receptor agonist induced neuroprotection in spinal cord injury is potentiated by antioxidant compound H-290/51, and Neuromodulation and quality of life for patient with spasticity after spinal cord injury, and much more.\u003cbr/\u003eOther sections cover Efficacy of invasive and non-invasive methods for the treatment of Parkinson Ìs disease: nanodelivery and enriched environment, Co-administration of DL-3-n-butylphthalide and neprilysin is neuroprotective in Alzheimer disease associated with brain injury, Nicotine Neurotoxicity Exacerbation following Engineered Ag and Cu (50-60 nm) nanoparticles intoxication. Neuroprotection with nanowired delivery of antioxidant compound H-290/51 together with serotonin 5-HT3 receptor antagonist ondansetron, and more.\u003cul\u003e\u003cli\u003eProvides the authority and expertise of leading contributors from an international board of authors\u003c/li\u003e\u003cli\u003ePresents the latest release in \u003ci\u003eInternational Review on Neurobiology\u003c/i\u003e series\u003c/li\u003e\u003cli\u003eUpdated release includes the latest information on \u003ci\u003eNanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-Morbidity Factors\u003c/i\u003e\u003c/li\u003e\u003c/ul\u003e |
nl
en
